List of Excipients in Branded Drug MYORISAN

Generic Drugs Containing MYORISAN

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	isotretinoin	54868-6366	.ALPHA.-TOCOPHEROL
Physicians Total Care Inc	isotretinoin	54868-6366	ALCOHOL
Physicians Total Care Inc	isotretinoin	54868-6366	AMMONIA
Physicians Total Care Inc	isotretinoin	54868-6366	BUTYL ALCOHOL
Physicians Total Care Inc	isotretinoin	54868-6366	BUTYLATED HYDROXYANISOLE
Physicians Total Care Inc	isotretinoin	54868-6366	EDETATE DISODIUM
Physicians Total Care Inc	isotretinoin	54868-6366	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in MYORISAN?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL
1	.ALPHA.-TOCOPHEROL, DL-
2	ALCOHOL
2	AMMONIA
2	BUTYL ALCOHOL
2	BUTYLATED HYDROXYANISOLE
2	EDETATE DISODIUM

# Myorisan Excipient Strategy and Commercial Opportunities in Isotretinoin Softgels

Last updated: August 9, 2026

Myorisan is an oral isotretinoin softgel historically marketed in 10 mg, 20 mg, 30 mg, and 40 mg strengths. Its formulation uses a lipid-based fill and gelatin capsule, with soybean oil, hydrogenated vegetable oils, gelatin, colorants, antioxidants, and chelating agents identified in product labeling. The main commercial opportunities are improved food-effect performance, reduced dependence on soybean-derived excipients, vegetarian or non-animal capsule systems, dose-flexible packaging, enhanced stability, and differentiated isotretinoin delivery technologies.[1]

Myorisan's excipient estate is commercially relevant because isotretinoin has poor aqueous solubility, variable absorption, teratogenic risk, and strict risk-management requirements. A reformulated product must preserve exposure while improving administration, tolerability, supply resilience, or patient access. The strongest opportunities are likely to arise from lipid-system redesign rather than from simple substitution of capsule colorants or minor processing aids.

What excipients are used in Myorisan capsules?

Myorisan uses a conventional isotretinoin softgel architecture. The labeled inactive ingredients include soybean oil, hydrogenated vegetable oils, gelatin, butylated hydroxyanisole, edetate disodium, titanium dioxide, FD&C Red No. 7, and strength- or shell-specific colorants.[1]

Formulation element	Myorisan role	Commercial significance
Isotretinoin	Active retinoid	Poorly water-soluble compound requiring solubilization in a lipid vehicle
Soybean oil	Primary lipid vehicle	Supports dissolution but creates allergen, sourcing, and labeling considerations
Hydrogenated vegetable oils	Lipid structuring and fill consistency	Improves physical stability and capsule-fill properties
Gelatin	Softgel shell	Established manufacturing platform but is animal-derived
Butylated hydroxyanisole	Antioxidant	Helps limit oxidative degradation of the retinoid and lipid phase
Edetate disodium	Chelating agent	Can reduce metal-catalyzed degradation pathways
Titanium dioxide and FD&C colorants	Capsule identification and appearance	Support dose differentiation and product recognition

The formulation is designed around solubilizing isotretinoin in an oil-based fill rather than dispersing the drug in an aqueous medium. That approach is consistent with isotretinoin's physicochemical profile and the historical design of many isotretinoin softgels.[1,2]

How does Myorisan's lipid formulation affect isotretinoin absorption?

Myorisan labeling instructs patients to take capsules with meals, reflecting the importance of dietary fat for absorption of conventional isotretinoin products.[1] Food-dependent absorption creates a clear formulation opportunity: a product that maintains exposure under lower-fat or more variable meal conditions can offer a practical clinical advantage.

The commercial problem with food-dependent isotretinoin

Conventional isotretinoin products can show materially higher exposure when taken with food, particularly a meal containing fat. Patients may take the medicine inconsistently with meals, reducing effective exposure and complicating dose management. For a teratogenic drug administered under the iPLEDGE risk-management framework, missed or poorly absorbed doses can also complicate treatment planning.[3]

A reformulator can target:

• More consistent exposure across fed and fasted conditions.
• Reduced reliance on a high-fat meal.
• Lower within-patient pharmacokinetic variability.
• Improved dissolution of the active ingredient.
• Smaller capsules or lower excipient mass.
• Better tolerance in patients who experience gastrointestinal effects from oily fills.

The commercial benchmark is Absorica, an isotretinoin formulation developed to improve bioavailability without requiring administration with food. Its label describes a lipid-based formulation with different absorption behavior from conventional isotretinoin products.[4] A Myorisan successor would need to demonstrate a meaningful pharmacokinetic or usability advantage over both conventional generic isotretinoin and food-independent competitors.

What excipient strategies could improve Myorisan?

1. Replace or reduce soybean oil

Soybean oil is a practical and established vehicle, but it can create commercial constraints. These include soybean-allergen labeling, raw-material qualification, oxidation control, and dependence on a commodity-derived supply chain.

Potential alternatives include:

• Medium-chain triglycerides.
• Long-chain triglycerides from non-soy sources.
• Caprylic and capric triglyceride systems.
• Mineral-oil-compatible lipid systems, where regulatory and tolerability requirements permit.
• Mixed triglyceride vehicles.
• Self-emulsifying drug-delivery systems.

A direct switch is unlikely to be sufficient by itself. The replacement vehicle would need to preserve isotretinoin solubility, limit precipitation during digestion, maintain capsule compatibility, and support comparable or improved exposure.

2. Use self-emulsifying or self-microemulsifying systems

Self-emulsifying drug-delivery systems can improve dispersion of lipophilic compounds in gastrointestinal fluids. A formulation may combine an oil phase with surfactants and co-solvents to generate fine droplets after administration.

The key development risks are surfactant-related gastrointestinal intolerance, capsule-shell interaction, long-term physical stability, and the need to establish a robust in vitro-in vivo relationship. The commercial benefit is strongest if the formulation reduces the food effect without relying on a large amount of surfactant.

3. Develop a non-gelatin capsule

Gelatin is widely used for softgels, but it is animal-derived and can create supply, religious, dietary, and sustainability limitations. Potential alternatives include hypromellose-based capsules and other polymeric shell systems.

A non-gelatin product could target:

• Vegetarian and certain religious-diet markets.
• Institutional buyers with animal-origin restrictions.
• Global markets with tighter excipient-origin requirements.
• Patients who prefer non-animal dosage forms.

The technical barrier is high. The shell must maintain oxygen and moisture protection, prevent migration of the lipid fill, withstand encapsulation, and remain stable over the full shelf life. A hard capsule with a liquid or semi-solid fill could be considered, but it would require careful control of leakage, sealing, and dose uniformity.

4. Improve oxidative stability

Isotretinoin and lipid excipients are sensitive to oxidation and light. Myorisan uses an antioxidant and a chelating agent as part of its stability strategy.[1] A next-generation product could evaluate:

• Alternative antioxidants.
• Tocopherol-based systems.
• Lower-peroxide lipid raw materials.
• Metal-ion control in manufacturing.
• Nitrogen blanketing.
• Higher-barrier blister packaging.
• Light-protective capsule shells.
• Oxygen-scavenging secondary packaging.

Stability improvements can reduce manufacturing losses and extend commercial shelf life. They can also support distribution in warmer or more humid markets, although packaging changes alone would not eliminate the need for formal stability studies.

What formulations are protected by isotretinoin patents?

Isotretinoin formulation protection has historically focused on delivery systems that modify bioavailability, food dependence, particle size, lipid vehicles, or capsule composition. A commercially relevant formulation patent would generally need claims directed to a defined composition, manufacturing process, pharmacokinetic profile, or method of administration.

Conventional Myorisan formulation

The conventional soybean-oil softgel design is mature and broadly understood. Commercial differentiation based only on the use of soybean oil, gelatin, hydrogenated vegetable oils, or standard antioxidants is likely to face limited defensibility unless the formulation includes a specific quantitative range or produces an unexpected performance result.

Food-independent formulations

Food-independent isotretinoin products have stronger differentiation potential because they address a clinically relevant limitation of conventional products. The key patent and regulatory evidence would include:

• Specific lipid or surfactant ratios.
• Defined particle-size distributions.
• Pharmacokinetic parameters under fasted conditions.
• Exposure equivalence or superiority.
• Reduced fed-to-fasted variability.
• Manufacturing controls that generate the claimed performance.

Such claims may be vulnerable to obviousness challenges if the formulation merely combines known lipid excipients without a demonstrated technical effect.

Manufacturing and process patents

Manufacturing protection may cover:

• Solubilization temperature and mixing sequence.
• Oxygen-control conditions.
• Encapsulation parameters.
• Fill viscosity.
• Crystallization control.
• Homogeneity and content-uniformity methods.
• Packaging configurations.

Process patents can create practical barriers even when composition claims are narrow. Their value depends on whether competitors can achieve comparable product quality through an alternative process.

What is the FDA regulatory status of Myorisan?

Myorisan was approved as an oral isotretinoin product in multiple capsule strengths. FDA-approved labeling identifies the product as an isotretinoin capsule and includes the required boxed warning, pregnancy-prevention information, and iPLEDGE-related requirements.[1,3]

Isotretinoin products are subject to a stringent risk-management framework because of the high risk of severe fetal harm. A new Myorisan formulation would need to address:

• FDA quality and bioequivalence requirements.
• Capsule-strength equivalence.
• Stability and impurity specifications.
• Drug-product dissolution.
• Food-effect studies where the formulation claims changed administration conditions.
• iPLEDGE operational requirements.
• Labeling for excipient-specific allergies or dietary considerations.

A reformulated product that changes absorption materially may not qualify for a simple product-line extension. Depending on the formulation and development pathway, FDA may require clinical pharmacology studies, comparative bioavailability studies, or a new drug application strategy rather than a straightforward generic substitution.[5]

What is the Orange Book status of Myorisan?

The Orange Book is the primary FDA reference for approved drug products, therapeutic-equivalence evaluations, patent listings, and exclusivity information.[6] Myorisan is associated with isotretinoin products historically marketed under NDA 021951, while other isotretinoin products have separate approval histories and sponsors.

The commercial implications are straightforward:

1. Conventional isotretinoin has a mature generic market.
2. The key barriers are formulation differentiation, regulatory approval, manufacturing quality, and risk-management compliance rather than basic active-ingredient exclusivity.
3. A new formulation may have its own patent estate even when the underlying isotretinoin molecule is no longer commercially exclusive.
4. Orange Book listing decisions must be reviewed at the product and patent-claim level.
5. A Paragraph IV challenge would be relevant only if an approved product has listed patents covering the proposed generic's formulation, method of use, or other listed subject matter.

No isotretinoin product should be evaluated solely by reviewing the active ingredient's age. Formulation and delivery patents can create separate commercial barriers.

When does Myorisan lose exclusivity?

Myorisan's commercial position is not defined by a single active-ingredient patent expiration date. Isotretinoin is an established active ingredient, and multiple generic and branded products have competed in the U.S. market. Any current exclusivity analysis must separate:

• Active-ingredient patent protection.
• Product-specific formulation patents.
• Method-of-use patents.
• Regulatory exclusivity.
• iPLEDGE-related operational restrictions.
• Supply and manufacturing constraints.

The practical conclusion is that a conventional Myorisan-like product faces generic competition. A reformulated product could pursue new patent protection based on a novel excipient system, improved pharmacokinetic behavior, or a differentiated dosage form. The strongest protection would combine composition claims with process and packaging claims.

Which companies compete with Myorisan?

The isotretinoin market has included conventional products such as Claravis, Amnesteem, Zenatane, and generic isotretinoin capsules, along with food-independent or differentiated products such as Absorica.[4,7]

Competitor type	Representative products	Competitive basis
Conventional softgels	Generic isotretinoin, Claravis, Amnesteem, Zenatane	Established lipid-filled capsule platform and price
Food-independent products	Absorica and related products	Reduced dependence on administration with a high-fat meal
Compounded products	Pharmacy-specific formulations	Customized strength or dosage form, subject to compounding rules
Future reformulations	Potential non-soy, non-gelatin, or microemulsion products	Excipient differentiation, patient preference, or pharmacokinetic performance

The market is price-sensitive for conventional products. A premium product requires a clear advantage that is visible to prescribers, patients, payers, or pharmacies.

What commercial opportunities exist for a Myorisan successor?

Premium food-independent isotretinoin

This is the most direct opportunity. A formulation that provides reliable exposure without a high-fat meal could compete with existing differentiated isotretinoin products. The product would need strong comparative pharmacokinetic data and a clear label statement.

Soy-free or reduced-soy isotretinoin

A non-soy lipid platform could address allergen concerns and reduce dependence on soybean-derived materials. The commercial opportunity is likely niche unless the product also improves food-effect performance or tolerability.

Vegetarian isotretinoin softgels

A non-gelatin shell could support differentiation in specialty pharmacy, institutional, and international channels. The product would need to preserve the manufacturing and stability performance of gelatin softgels.

Flexible dose delivery

Isotretinoin dosing is commonly adjusted according to response, tolerability, cumulative exposure, and laboratory findings. A product with improved strength combinations, smaller capsules, or a controlled-dose platform could reduce the need for complex capsule combinations.

Improved packaging and stability

High-barrier blister packs, unit-dose packaging, and better light and oxygen protection could support long-term stability and reduce dispensing errors. Packaging alone is unlikely to command a large premium but can strengthen a broader product proposition.

Contract manufacturing and licensing

A company with a validated lipid formulation, non-gelatin shell technology, or encapsulation process could license the platform to generic manufacturers. Potential partners include firms with established isotretinoin distribution, dermatology portfolios, or REMS-compliant pharmacy infrastructure.

What generic entry risks exist for a reformulated Myorisan product?

A conventional generic entrant can compete on price if it demonstrates pharmaceutical equivalence and therapeutic equivalence. A differentiated reformulation faces several risks:

• A competitor may design around composition claims with a different lipid vehicle.
• Food-effect advantages may be difficult to translate into payer reimbursement.
• Excipients may create new safety or tolerability concerns.
• Novel surfactants may complicate regulatory review.
• Non-gelatin shells may increase manufacturing cost.
• Limited isotretinoin market growth may constrain return on development investment.
• iPLEDGE compliance can increase operational burden for every product in the category.

The most defensible product would combine a clinically meaningful absorption advantage with broad composition claims, process claims, packaging claims, and a strong regulatory label.

How strong is the patent estate for a Myorisan excipient strategy?

A conventional soybean-oil and gelatin softgel strategy would likely have limited standalone patent strength because those excipient classes are established in oral softgel manufacturing. Patent strength improves when the formulation includes a defined technical result that competitors cannot easily reproduce.

A practical patent program could include:

Claim category	Potential subject matter	Relative value
Composition	Specific lipid, surfactant, antioxidant, and isotretinoin ratios	High if tied to improved exposure
Pharmacokinetic performance	Fasted exposure or reduced fed-fasted variability	High but requires strong data
Capsule shell	Non-gelatin polymer system compatible with isotretinoin fill	Moderate to high
Manufacturing process	Oxygen control, mixing, encapsulation, or crystallization control	Moderate
Packaging	High-barrier blister or oxygen-control configuration	Moderate
Method of use	Administration without a high-fat meal	Depends on statutory and prior-art analysis

The estate should be drafted across the United States, Europe, Japan, Canada, and major dermatology markets. International value depends on local rules for formulation patents, therapeutic-use claims, and patent-term adjustments.

Key Takeaways

• Myorisan uses a conventional lipid-filled gelatin softgel platform for isotretinoin.
• Soybean oil, hydrogenated vegetable oils, antioxidants, chelating agents, gelatin, and colorants are central formulation components.[1]
• The leading technical opportunity is reducing the food effect while preserving isotretinoin exposure.
• Soy-free lipid vehicles and non-gelatin shells offer differentiated positioning but require substantial compatibility and stability work.
• Conventional excipient substitution alone is unlikely to create strong patent protection.
• A commercially durable product should combine formulation, process, packaging, and pharmacokinetic claims.
• FDA approval and iPLEDGE compliance remain essential commercial requirements.
• Conventional isotretinoin faces generic price competition, so premium positioning requires a measurable patient or prescriber benefit.
• Licensing opportunities are strongest for validated food-independent delivery systems and scalable non-animal softgel technologies.

FAQs

Can soybean oil be replaced in Myorisan?

Yes. Medium-chain triglycerides, mixed triglycerides, and self-emulsifying lipid systems are possible alternatives. The replacement must preserve isotretinoin solubility, stability, capsule compatibility, and bioavailability.

Would a vegetarian Myorisan capsule require a new FDA application?

Possibly. A shell change may require comparative quality and bioavailability work. If the change materially affects release or absorption, FDA may require a more extensive regulatory package.

Is isotretinoin a good candidate for a self-emulsifying drug-delivery system?

Yes. Its poor aqueous solubility and food-dependent absorption make it technically suitable for lipid-based dispersion systems. Surfactant tolerability and stability are the principal development issues.

Can a Myorisan reformulation receive new patent protection?

Yes, if it contains patentable composition, process, packaging, or administration features that are novel and non-obvious. The strongest claims would be supported by demonstrated pharmacokinetic or stability improvements.

Does iPLEDGE create a market barrier for new isotretinoin products?

Yes. iPLEDGE compliance adds operational and regulatory requirements for manufacturers, prescribers, pharmacies, and patients. It also raises the cost of launching and maintaining a new isotretinoin product.[3]

References

1. U.S. Food and Drug Administration. (2020). Myorisan (isotretinoin) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2023). Inactive ingredient database.
3. U.S. Food and Drug Administration. (2024). iPLEDGE Risk Evaluation and Mitigation Strategy.
4. U.S. Food and Drug Administration. (2024). Absorica (isotretinoin) capsules: Prescribing information.
5. U.S. Food and Drug Administration. (2022). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
7. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products database.